Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared on LinkedIn:
“List of 12 Approvals given in breast cancer by FDA from 1st May 2026 till 16 th November 2026. For quick summary.
1․ 1 May 2026։ Vepdegestrant
ER-positive, HER2-negative, ESR1-mutated advanced/metastatic breast cancer with progression after at least one line of endocrine therapy.
2․ 15 May 2026 T-DXd – THP
Neoadjuvant treatment of HER2-positive (IHC 3+ or ISH+) stage II–III early breast cancer.
FDA Approves T-DXd for Two Early HER2-Positive Breast Cancer Settings

3․ 15 May 2026 Adjuvant T-DXd
HER2-positive early breast cancer with residual invasive disease after neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment.
4․ 22 May 2026 Datopotamab Deruxtecan
Unresectable or metastatic TNBC in adults who are not candidates for PD-1/PD-L1 inhibitor therapy.
Datopotamab Deruxtecan Improves PFS and OS in First-Line Advanced TNBC in TROPION-Breast02

5․ 24 June 2026 Sacituzumab Govitecan
First-line treatment of unresectable locally advanced or metastatic TNBC in adults not candidates for PD-1/PD-L1 inhibitor-based therapy.
FDA Approves Sacituzumab Govitecan Plus Pembrolizumab for First-Line PD-L1–Positive TNBC

6․ 24 June 2026 Sacituzumab Govitecan + Pembrolizumab
First-line treatment of unresectable locally advanced or metastatic TNBC with PD-L1 CPS ≥10. (FDA also permits pembrolizumab + berahyaluronidase alfa-pmph formulation.)
Sacituzumab Govitecan Plus Pembrolizumab Improves First-Line Outcomes in PD-L1 Positive Advanced Triple-Negative Breast Cancer

7․ 24 June 2026 Palbociclib + Trastuzumab ± Pertuzumab + Endocrine therapy
Maintenance treatment of HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
FDA Approves Palbociclib-Based Maintenance Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer

8․ 14 July 2026 Gedatolisib + Fulvestrant ± Palbociclib
HR-positive, HER2-negative locally advanced/metastatic breast cancer without a detected PIK3CA mutation, after progression on or after at least one line of endocrine therapy in the metastatic setting.
9․ 4 September 2026 Camizestrant + CDK4/6 inhibitor
Accelerated approval: HR-positive, HER2-negative locally advanced/metastatic breast cancer upon detection of an ESR1 mutation during aromatase inhibitor + CDK4/6 inhibitor therapy.
AstraZeneca’s Camizestrant Faces FDA ODAC Review In ESR1-Mutated HR+/HER2− Breast Cancer

10․ 18 September 2026 Imlunestrant + Abemaciclib
ER-positive, HER2-negative, ESR1-mutated advanced/metastatic breast cancer with progression after at least one line of endocrine therapy.
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer After Endocrine Therapy

11․ 7 October 2026 Tucatinib + Trastuzumab + Pertuzumab
Maintenance treatment of unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
FDA Approves Tucatinib as Front-Line Maintenance in HER2-Positive Metastatic Breast Cancer

12․ 16 November 2026 Giredestrant + Everolimus
ER-positive, HER2-negative, ESR1-mutated locally advanced/metastatic breast cancer with recurrence during/after endocrine-based adjuvant therapy OR progression on at least one endocrine-based regimen in the metastatic setting.
Source: US FDA approval announcements. Count is indication-based, not 12 new drugs.
Find out more:

